CN201935922U - Rapid detection test paper for bladder cancer BLCA-4 protein urine - Google Patents
Rapid detection test paper for bladder cancer BLCA-4 protein urine Download PDFInfo
- Publication number
- CN201935922U CN201935922U CN2010206907965U CN201020690796U CN201935922U CN 201935922 U CN201935922 U CN 201935922U CN 2010206907965 U CN2010206907965 U CN 2010206907965U CN 201020690796 U CN201020690796 U CN 201020690796U CN 201935922 U CN201935922 U CN 201935922U
- Authority
- CN
- China
- Prior art keywords
- pad
- blca
- test paper
- carcinoma
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model discloses a rapid detection test paper for bladder cancer BLCA-4 protein urine, which comprises a back lining, and a sample cushion, a combined cushion and a detection cushion which are arranged on the back lining and are connected from left to right in sequence; the combined cushion is provided with a labeled antibody composite layer formed by combining colloidal gold with anti-BLCA-4 monoclonal antibody; the detection cushion is transversely provided with an anti-BLCA-4 polyclonal antibody detection line; the rapid detection test paper for bladder cancer BLCA-4 protein urine is strong in detection specificity, high in sensitivity, simple and convenient in operation, direct and reliable in judged result and easy to grasp, and provides a convenient and reliable method for the sieving and detection of bladder cancer in large-scale crowd and for the self-detection of the patients after bladder cancer operation.
Description
Technical field
The utility model relates to a kind of detection test paper, particularly a kind of carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper.
Background technology
" goldstandard " of carcinoma of urinary bladder postoperative check at present is cystoscopy+urine exfoliative cytology inspection.The method of getting the pathological tissues biopsy by cystoscope is the most reliable method of diagnosing bladder cancer, but a kind of traumatic inspection, sense of discomfort is strong in the checking process, the symptom that generally can occur blood urine, paruria after the inspection even infect, make many patients can not tolerate, adhere to, and cystoscopic susceptibility and accuracy and supervisory personnel's experience is closely related, for carcinoma in situ and diseased region mucous membrane the obviously early lesion of change does not take place, and cystoscopy susceptibility is poor, the rate of missed diagnosis height; The specificity of urine exfoliative cytology inspection can reach 85-100%, but susceptibility has only 13-75%, and is subjected to the influence of factors such as inflammation, calculus, perfusion in the bladder easily; The ultrasonic method that can be used as a kind of check and examination of bladder, but also fail to pinpoint a disease in diagnosis easily for early lesion, same, ultrasonographic susceptibility and accuracy are also closely related with supervisory personnel's experience.Therefore, press for and seek a kind of Wicresoft or even do not have the high carcinoma of urinary bladder detection method of wound, susceptibility and specificity.
The main part of carcinoma of urinary bladder is immersed in the urine, and the product of cancer cell secretion and the product of downright bad apoptotic cell also enter in the urine, should be a kind of convenience, noninvasive inspection method by the urine detection tumor markers therefore.Have been found that the tumor-marker albumen of multiple carcinoma of urinary bladder at present, wherein, tumor of bladder specificity nuclear matrix protein 4(BLCA-4) more and more come into one's own.BLCA-4 is an a kind of albumen that is expressed in the transitional cell bladder carcinoma cell line nuclear, in the multiple fission of tumour cell, play an important role, can be discharged in the urine along with the dissolving of apoptotic nucleus, and this albumen is not expressed at normal bladder tissue, therefore have the specificity of height.Studies show that, adopt the BLCA-4 albumen in the immunization mensuration bladder cancer patients urine, susceptibility reaches 96%, specificity reaches 100%, far above other tumor markers, and maximum advantage is early stage carcinoma of urinary bladder also to be had well detect effect, and is not subjected to the influence of factors such as inflammation, calculus, perfusion in the bladder.The clinical detection of urine BLCA-4 albumen mainly adopts enzyme-linked immunosorbent assay (ELISA) method to detect at present, but this method needs specific apparatus and professional, and complicated operation, consuming time, the expense costliness, can not satisfy accurate, sensitive, quick, economic inspection requirements, patient can't monitor the state of an illness of oneself at home.
Up to now, do not see the research report of relevant carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper.
Summary of the invention
In view of this, the purpose of this utility model is at the deficiencies in the prior art, and species specificity and highly sensitive, carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper easily and fast are provided.
For achieving the above object, the utility model adopts following technical scheme:
Carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper of the present utility model, on comprising backing and being arranged on backing and the sample pad, pad and the detecting pad that link to each other successively from left to right, described pad is provided with the golden labeling antibody composite layer that collaurum combines with the monoclonal antibody of anti-BLCA-4, is horizontally arranged with the polyclonal antibody detection line of anti-BLCA-4 on the described detecting pad.
Further, also comprise the imbibition pad that is fixedly installed on the backing, described detecting pad one end links to each other with pad, and the other end links to each other with the imbibition pad;
Further, be provided with the two anti-nature controlling lines of the anti-mouse parallel on the described detecting pad between detection line and the imbibition pad with detection line;
Further, described detecting pad is attached on the backing, and pad is positioned at detecting pad top overlaps with it, and the imbibition pad is positioned at detecting pad top overlaps with it, and sample pad is positioned at pad top and overlaps with it;
Further, described detecting pad is a nitrocellulose filter;
Further, described sample pad and pad are the plain film of glass fibre.
The beneficial effects of the utility model are: carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper detection specificity of the present utility model is strong, highly sensitive, easy and simple to handle, that the result judges is intuitive and reliable, be easy to grasp, for the large-scale crowd examination of carcinoma of urinary bladder, the oneself of carcinoma of urinary bladder postoperative patient detect the reliable method of providing convenience; The utility model will detect BLCA-4 albumen and colloidal gold immunity chromatography combines, be a up-and-coming carcinoma of urinary bladder fast detecting, screening method, increase case and recurrent cases newly, take effective treatment, raising patients ' life quality, saving health resources early for early detection, significant.
Description of drawings
In order to make the purpose of this utility model, technical scheme and advantage clearer, below in conjunction with accompanying drawing the utility model is described in further detail, wherein:
Fig. 1 is a structural representation of the present utility model;
Fig. 2 be Fig. 1 along A-A to cut-open view.
Embodiment
Hereinafter with reference to accompanying drawing, preferred embodiment of the present utility model is described in detail.
Fig. 1 is a structural representation of the present utility model, Fig. 2 be Fig. 1 along A-A to cut-open view, as shown in the figure: the carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper of present embodiment, on comprising backing 7 and being arranged on backing 7 and the sample pad 1, pad 2 and the detecting pad 3 that link to each other successively from left to right, described pad 2 is provided with the golden labeling antibody composite layer 8 that collaurum combines with the monoclonal antibody of anti-BLCA-4, is horizontally arranged with the polyclonal antibody detection line 4 of anti-BLCA-4 on the described detecting pad 3.
In the present embodiment, also comprise the imbibition pad 6 that is fixedly installed on the backing 7, described detecting pad 3 one ends link to each other with pad 2, and the other end links to each other with imbibition pad 6; Imbibition pad 6 is an absorbent filter, remaining urine after effectively absorption detecting is finished, neat and tidy.
In the present embodiment, be provided with the two anti-nature controlling lines 5 of the anti-mouse parallel on the described detecting pad 3 between detection line 4 and the imbibition pad 6 with detection line 4; Can decision operation whether slip up or detect test paper by nature controlling line 5 and whether lost efficacy, whether need to detect again, to improve the accuracy that detects.
In the present embodiment, described detecting pad 3 is attached on the backing 7, and pad 2 is positioned at detecting pad 3 tops overlaps with it, and imbibition pad 6 is positioned at detecting pad 3 tops overlaps with it, and sample pad 1 is positioned at pad 2 tops and overlaps with it; Adopt this structure, can make the detection test paper have chromatography effect preferably.
In the present embodiment, described detecting pad 3 is a nitrocellulose filter.
In the present embodiment, described sample pad 1 and pad 2 are the plain film of glass fibre.
During use, urine to be measured drops on the sample pad 1, and urine is absorbed by sample pad 1 and by the imbibition pad 6 end chromatographies of capillary action to the detection test paper, when flowing through pad 2, the golden labeling antibody on the pad 2 just can be dissolved; If contain the BLCA-4 proteantigen in the urine to be measured, it will form " collaurum-Ag-Ab " complex with golden labeling antibody reaction back, when this complex moves to detection line 4 on the nitrocellulose filter with capillary action, react with polyclonal antibodies in the detection line 4 and be trapped, collaurum forms macroscopic red stripes at the place of holding back, when unnecessary golden labeling antibody moves to nature controlling line 5, close with two resistive connections and condense colour developing, therefore, when the detection line 4 on detecting test paper all shows red with nature controlling line 5, be judged to positive findings; Otherwise, if do not contain the BLCA-4 proteantigen in the urine to be measured, just can not form " collaurum-Ag-Ab " complex, golden labeling antibody is only arranged, and it is red that detection line 4 does not show, and golden labeling antibody is when moving to nature controlling line 5, close with two resistive connections and condense colour developing, therefore, the detection line 4 on detecting test paper does not show redness and nature controlling line 5 when showing red, is judged to negative findings; When the nature controlling line 5 that detects test paper did not show red, no matter whether detection line 4 shows red, the result was judged to misoperation or detects test paper and lost efficacy, and needs to detect again.
Explanation is at last, above embodiment is only unrestricted in order to technical scheme of the present invention to be described, although by invention has been described with reference to the preferred embodiments of the present invention, but those of ordinary skill in the art is to be understood that, can make various changes to it in the form and details, and the spirit and scope of the present invention that do not depart from appended claims and limited.
Claims (6)
1. carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper, comprise backing (7) and be arranged on sample pad (1), pad (2) and the detecting pad (3) that backing (7) is gone up and linked to each other successively from left to right, it is characterized in that: described pad (2) is provided with the golden labeling antibody composite layer (8) that collaurum combines with the monoclonal antibody of anti-BLCA-4, is horizontally arranged with the polyclonal antibody detection line (4) of anti-BLCA-4 on the described detecting pad (3).
2. carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper according to claim 1, it is characterized in that: also comprise the imbibition pad (6) that is fixedly installed on the backing (7), described detecting pad (3) one ends link to each other with pad (2), and the other end links to each other with imbibition pad (6).
3. carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper according to claim 2 is characterized in that: described detecting pad (3) is gone up the two anti-nature controlling lines (5) that are provided with the anti-mouse parallel with detection line (4) between detection line (4) and the imbibition pad (6).
4. carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper according to claim 3, it is characterized in that: described detecting pad (3) is attached on the backing (7), pad (2) is positioned at detecting pad (3) top and overlaps with it, imbibition pad (6) is positioned at detecting pad (3) top overlaps with it, and sample pad (1) is positioned at pad (2) top and overlaps with it.
5. according to any described carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper of claim 1 to 4, it is characterized in that: described detecting pad (3) is a nitrocellulose filter.
6. according to any described carcinoma of urinary bladder BLCA-4 albumen urine quick detection test paper of claim 1 to 4, it is characterized in that: described sample pad (1) and pad (2) are the plain film of glass fibre.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010206907965U CN201935922U (en) | 2010-12-30 | 2010-12-30 | Rapid detection test paper for bladder cancer BLCA-4 protein urine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010206907965U CN201935922U (en) | 2010-12-30 | 2010-12-30 | Rapid detection test paper for bladder cancer BLCA-4 protein urine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201935922U true CN201935922U (en) | 2011-08-17 |
Family
ID=44447440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010206907965U Expired - Fee Related CN201935922U (en) | 2010-12-30 | 2010-12-30 | Rapid detection test paper for bladder cancer BLCA-4 protein urine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201935922U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103267848A (en) * | 2013-05-22 | 2013-08-28 | 苏州市马尔泰新材料有限公司 | CRISP1 (cystein-rich secretory protein 1) kit for quickly diagnosing gingival carcinoma |
-
2010
- 2010-12-30 CN CN2010206907965U patent/CN201935922U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103267848A (en) * | 2013-05-22 | 2013-08-28 | 苏州市马尔泰新材料有限公司 | CRISP1 (cystein-rich secretory protein 1) kit for quickly diagnosing gingival carcinoma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2956723C (en) | System and method for monitoring health based on collected bodily fluid | |
| Saito et al. | Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case‐control study | |
| JP3129738B2 (en) | Test patch and test method | |
| JP5335802B2 (en) | Method and apparatus for detecting occult blood | |
| AR107561A2 (en) | ELISA TEST FOR VEGF DETECTION | |
| US9144520B2 (en) | Noninvasive detection of meconium in amniotic fluid | |
| CN101221180B (en) | Portable fast joint inspection device for multiple tumor marker | |
| KR20150023721A (en) | Methods and compositions for personalized medicine by point-of-care devices for fsh, lh, hcg and bnp | |
| US20100256464A1 (en) | Device for determining risk of developing breast cancer and method thereof | |
| Abebe et al. | Variation of urine parameters among diabetic patients: A cross-sectional study | |
| Naseri et al. | Comparative assessment of serum versus menstrual blood for diagnostic purposes: a pilot study | |
| CN105785028A (en) | Rapid diagnosis kit for detecting novel human cardiac failure marker ST2 | |
| CN201935922U (en) | Rapid detection test paper for bladder cancer BLCA-4 protein urine | |
| JP2008547002A (en) | Methods for diagnosing and treating cerebrovascular events based on NR2 peptides | |
| CN202916284U (en) | NGAL (neutrophil gelatinase associated lipocalin) whole blood detecting device | |
| JP5437062B2 (en) | A method for determining gastric mucosal status by quantitative measurement of fecal Helicobacter pylori antigen | |
| KR101142434B1 (en) | Method for noninvasive prediction or diagnosis of inflammation and infection in amniotic fluid of patients with premature rupture of membranes | |
| CN201196650Y (en) | Portable fast joint inspection device for multiple tumor tokens | |
| CN207007856U (en) | The kit of hemoglobin in a kind of quick detection excrement | |
| CN107091927A (en) | A kind of kit for diabetogenous nephrosis disease early diagnosis | |
| Al-Jaroudi et al. | Non-Alcoholic fatty liver disease in infertile women with polycystic ovarian syndrome: a prospective series | |
| CN106124498A (en) | Occult blood detection kit and application thereof | |
| CN203083998U (en) | Set of colloidal gold test paper for detecting bladder cancer | |
| CN1465978A (en) | Quick check test paper strip for oophoroma | |
| CN202676704U (en) | Test strip used for detecting NGAL (neutrophil gelatinase-associated lipocalin) colloidal gold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110817 Termination date: 20111230 |